劲方医药召开GFH375 III期注册性研究全国会议

医药健闻
Feb 12

(医药健闻2026年2月12日讯)劲方医药(2595.HK)近日成功召开GFH375III期注册性研究的全国研究者会议。此项研究(GFH375X1301,麒麟-翼01)于2025年11月在首家中心启动,针对胰腺癌KRAS突变占比最高的G12D突变型患者开展,为全球首个口服KRAS G12D抑制剂的III期研究。来自全国的数十家研究中心专家代表齐聚北京,围绕项目的既往入组经验、治疗效果、以及后续...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10